Showing results (181-190 of 222) with videos related to

Sort By:
Pageof 23
Frontiers in Oncology|October 3, 2022
Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNAUmang Swami, Raquel Mae Zimmerman, Roberto H Nussenzveig, et al.
The Journal of Clinical Investigation|July 15, 2024
Molecular analysis of primary and metastatic sites in patients with renal cell carcinomaShuchi Gulati, Pedro C Barata, Andrew Elliott, et al.
Journal of Pain and Symptom Management|May 5, 2025
Olanzapine for Managing Side Effects From Antiangiogenic Tyrosine-Kinase InhibitorsRegina M Koch, Miguel Muniz, Candy S Peskey, et al.
Cell|June 16, 2018
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate CancerYi-Mi Wu, Marcin Cieślik, Robert J Lonigro, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|October 15, 2013
Attainment of metabolic goals in the integrated UK islet transplant program with locally isolated and transported preparationsA M Brooks, N Walker, A Aldibbiat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2018
Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid TumorsDaniel D Von Hoff, Drew W Rasco, Elisabeth I Heath, et al.
The Lancet. Oncology|May 15, 2021
Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trialEvan Y Yu, Daniel P Petrylak, Peter H O'Donnell, et al.
European Urology|May 29, 2024
Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) TrialPrimo N Lara, Catherine Tangen, Elisabeth I Heath, et al.
Lancet (London, England)|July 31, 2023
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trialChristopher W Ryan, Catherine M Tangen, Elisabeth I Heath, et al.
JCO Precision Oncology|February 15, 2019
Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials ConsortiumMaria I Carlo, Veda N Giri, Channing J Paller, et al.
Pageof 23